Management of complications of cirrhosis in patients awaiting liver transplantation  Andres Cardenas, Pere Ginès  Journal of Hepatology  Volume 42, Issue 1, Pages S124-S133 (April 2005) DOI: 10.1016/j.jhep.2004.12.007 Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Treatment strategies for Grade 2 and 3 ascites. Low sodium diet is recommended with 70–90mmol/day. Recommended diuretics include spironolactone (50–200mg/day) or amiloride (5–10mg/day). Low doses of furosemide (20–40mg/day) may be added to increase natriuresis in patients with peripheral edema. Albumin replacement is 8g per liter tapped. Diuretics may be increased every week up to 400mg/day of spironolactone and 160mg/day of furosemide if there is no response. [This figure appears in colour on the web.] Journal of Hepatology 2005 42, S124-S133DOI: (10.1016/j.jhep.2004.12.007) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Treatment strategy for patients with refractory ascites. *Consider use of Transjugular intrahepatic portosystemic shunt (TIPS) in patients with preserved hepatic function, no hepatic encephalopathy, compartmentalized fluid, and those having repeated paracentesis more than 3–4× per month. [This figure appears in colour on the web.] Journal of Hepatology 2005 42, S124-S133DOI: (10.1016/j.jhep.2004.12.007) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Treatment strategy for patients with hepatorenal syndrome. Terlipressin is widely used in Europe but is not available in many countries including the United States. [This figure appears in colour on the web.] Journal of Hepatology 2005 42, S124-S133DOI: (10.1016/j.jhep.2004.12.007) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Treatment strategy for patients with acute variceal bleeding. Shunt surgery is reserved for patients with Child A cirrhosis. [This figure appears in colour on the web.] Journal of Hepatology 2005 42, S124-S133DOI: (10.1016/j.jhep.2004.12.007) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions